IGF1R and plasma cell myeloma: STAT3 inhibition upon NT157 treatment has also been described in other solid tumor cell lines and in multiple myeloma.23,24 Flashner-Abramson et al.23 described that in a melanoma cell line, NT157 inhibited STAT3 in a phosphatase-dependent and IGF1R/IRS-independent manner.